Steel Partners, an existing InMode shareholder, has made an unsolicited $16.75-per-share cash acquisition offer, challenging a competing CEO-led buyout proposal. The bid values InMode at roughly $500 million and represents a material premium to prior trading levels. InMode manufactures the Morpheus8 RF microneedling platform and Lumenis-derived laser systems—core revenue drivers for high-margin medspa workflows. A change in control could reshape device pricing, loyalty rebates, and service terms. Steel Partners' playbook typically involves operational efficiency and margin optimization, which may translate to tighter pricing for end-users or shifts in the rebate structure (similar to the Alle/Aspire dynamics in toxin and filler markets). The outcome will likely determine whether InMode remains an independent innovator or becomes part of a larger roll-up. Either path carries implications for practices that have built workflows around Morpheus8 or rely on InMode's service and upgrade cycles.